expression quantitative loci (eQTL) analyses of the 4 replicated SNPs in lung tissue and epithelium.
Results: Of the 790 asthmatics, 178 (23%) had ClinR and 55 ComR (7%) after median follow-up of 15.5 (range 3.3-47.8) years. In ClinR, 1 of the 25 SNPs, rs2740102, replicated in a meta-analysis of the replication cohorts, which was an eQTL for POLI in lung tissue. In ComR, 3 SNPs replicated in a meta-analysis of the replication cohorts. The top-hit, rs6581895, almost reached genome-wide significance (P-value 4.68 9 10 À7 ) and was an eQTL for FRS2 and CCT in lung tissue. Rs1420101 was a cis-eQTL in lung tissue for IL1RL1 and IL18R1 and a trans-eQTL for IL13.
Conclusions and Clinical Relevance:
By defining a strict remission phenotype, we identified 3 SNPs to be associated with complete asthma remission, where 2 SNPs have plausible biological relevance in FRS2, CCT, IL1RL1, IL18R1 and IL13.
| INTRODUCTION
Asthma is a highly prevalent chronic airway disease that affects over 300 million subjects worldwide. Asthma symptoms usually start in childhood, but not all preschool wheezers will continue to have asthma symptoms in childhood. In a birth cohort of asthmatic children diagnosed before the age of 6 and followed till 12 years of age, 1 asthma remission was present in 48% of the children when defined as the absence of any asthma events (hospitalization and/or physician visit) between the ages 6 and 11 years.
In contrast, asthma remission is less common in adults. We previously defined 2 types of remission, 2 one being "clinical remission,"
where asthmatics lose their symptoms for at least 12 months without using asthma treatment. This type of remission occurred in 52% of adult asthmatics. In contrast, remission occurred only in 22% of asthmatics when defined as "complete remission." The latter type had clinical remission and additionally met the more stringent criteria of normal lung function and absence of bronchial hyperresponsiveness (BHR), a hallmark of asthma. 2 In an observational study in adults with and without complete asthma remission, we found that those with complete remission lacked inflammatory infiltration of the airway mucosa, suggesting the inflammatory response had faded away. 3 This was supported by the observation that individuals with complete asthma remission did not develop sputum eosinophilia after inhaling adenosine monophosphate, 4 a trigger previously shown to attract eosinophils to sputum in asthmatics, independently of the use of inhaled corticosteroids. 5 Genome-wide association (GWA) studies have provided insights into the origins of asthma, and multiple genes have been associated with asthma development and subsequently replicated, such as the ORMDL3 region, IL1RL1, IL33 and TSLP. 6 This has led to some promising novel asthma treatments like anti-TSLP. 7 However, despite better treatments, there is still no cure for asthma. We hypothesized that genetics also plays a role in asthma remission and that the genes associated with asthma remission may differ from those associated with the development of asthma. Therefore, we performed a GWA study on asthma remission to provide us with clues to develop a cure for asthma. We investigated a Dutch identification cohort of 790 asthmatics initially characterized by the presence of a doctor diagnosis of asthma and BHR and assessed their remission status after a median 15.5 years of follow-up. We verified our findings in 2 European cohorts using the same phenotypic criteria and finally we performed expression quantitative loci (eQTL) analyses to determine allelic effects on gene expression in lung tissue and epithelial cells.
| METHODS

| Study population
We included 790 subjects from a long-term follow-up cohort with a doctor diagnosis of asthma and a positive BHR test at baseline. All participants who were younger than 12 years at baseline had an additional follow-up visit during early adulthood in which the persistence of asthma was confirmed by symptoms and objective measures during a clinic visit. All subjects had at least one follow-up measurement during adulthood (>18 years) in which their asthma status was evaluated by questionnaires and in most patients additionally with spirometry and a BHR test. All subjects participated in asthma studies performed at the University Medical Center Gronin- 
| Definition of asthma remission
Clinical remission (ClinR) at follow-up visit was defined as the absence of asthma symptoms (no wheezing without having a cold in the last year and no asthma attacks in the last 3 years) and no use For each analysis, the top 25 SNPs (after excluding SNPs in LD and regardless of their P-value) were analysed in 2 replication cohorts. The results of the replication cohorts were meta-analysed using METAL. 18 We assessed the direction of the effect in the identification cohort, that is a negative effect implying a lower chance of asthma remission, and a positive effect implying higher a chance of asthma remission. Significant replication was achieved if the direction of the effect in this meta-analysis was the same as in the identification cohort, and if the 1-sided P-value was <.05 (expected direction based on the identification analysis).
| Replication cohorts
Replication was performed in the EGEA-study 19 and the SAPALDIA cohort-study. [20] [21] [22] Extensive information on these cohorts is presented in the Supporting information. All subjects with doctordiagnosed asthma irrespective of age of onset and a positive BHR test at the baseline visit (early 1990s) were included in the current analysis. Remission status was determined at the most recent follow-up visit according to the same definitions as used in the identification cohort.
| Gene expression analysis in lung tissue and lung epithelial cells
The 4 significantly replicated SNPs were assessed for their association with cis-and trans-acting gene expression (mRNA) in lung tissue (n = 1087). 23 Subsequently, significant eQTLs identified in lung tissue were analysed in an epithelial-specific eQTL database (n = 85) (see Supporting information). were more often male, had a longer duration of follow-up, were younger at baseline and had a better lung function at baseline compared to subjects with PersA. The age of asthma onset was comparable between ClinR and PersA, while subjects in ComR had a younger age at the start of their asthma compared to PersA. Table 1 also shows the characteristics in the replication cohorts. In EGEA (n = 351), 23% of the subjects were in ClinR and 2% in ComR. In SAPALDIA (n = 105), these percentages were 51% and 13%, respectively.
| RESULTS
| Subject characteristics
| Clinical asthma remission
The results of the identification GWAS on ClinR are shown in Fig (Table 2) show that 1 of the 25 SNPs tested, rs7240102, met the criteria for significant replication (see Figure S6 for regional association plot).
| Complete asthma remission
The results of the identification GWAS on ComR are shown in Fig Male sex, n (%)
284 (46) 105 (59) 41 (75) 165 (61) 46 (57) 4 (57) 24 (47) 17 (32) 4 (29) Age at remission status, years 437 (74) 130 (80) 42 (86) 195 (72) 59 (73) 5 (71) 20 (44) 25 (56) 10 (22) Data are presented as median (25th percentile-75th percentile) unless indicated otherwise. Bold values signify significant differences from persistent asthma with P < 0.05 in the identification cohort.
In the meta-analysis of the identification and replication cohorts, the top-hit rs6581895 had a P-value of 4.68 9 10 À7 , very close to the Bonferroni-corrected genome-wide significant P-value of 3.1 9 10
À7
. (Table S2 ). In addition, rs1420101 was a trans-eQTL for Interleukin 13 (IL13) expression.
| Gene expression analysis in lung tissue
| Gene expression analysis in lung epithelial cells
The significant eQTLs identified in the lung tissue analysis were further explored in an epithelial specific eQTL database. None of the SNPs showed a significant association (Table S3 ).
| DISCUSSION
The goal of our study was to identify genetic markers associated with asthma remission by performing a genome-wide association study.
This may provide insight into mechanisms underlying asthma remission and possible provide us with clues to develop a cure for asthma.
We applied a restrictive asthma remission phenotype and defined | 1291 affect angiogenesis as well as actin reorganization. 25 If the latter is impaired, this might contribute to a reduced load and resolution of inflammation. 25 Finally, changes in this receptor may affect the function of multiple FGFs, some previously associated with lung development or disease, including FGF10 27 and FGF7. ing involvement in the maintenance of cell proliferation. 30 We found that the A-allele of rs1420101, a SNP located in IL1RL1, is associated with a lower chance for complete asthma remission in our adult asthma patients. This seems remarkable, as this rs1420101 A-allele has been identified previously as a risk for asthma in GWAS. 31 The A-allele of this IL1RL1 variant was associated with lower IL1RL1 and IL18R1 lung tissue expression 32 and
higher IL13 lung tissue expression in our study. Moreover, it was also associated with higher numbers of eosinophils in childhood asthma and with a higher risk for asthma in a previous study. 33 This suggests that higher IL1RL1 expression might eventually, and perhaps in association with other factors, contribute to remission of asthma by negatively regulating Type 2 inflammation as reflected by lower lung IL13 mRNA levels. IL1RL1 encodes 3 splice variants, and the synonymous asthma SNP rs1420101 is located in exon 5E, which is only retained in the transcript encoding the truncated IL-1RL1-c, also called ST2V. 34 This might indicate an effect of rs1420101 on this specific transcript. However, this variant is not supported by refseq annotation and the function of this transcript is yet unknown.
We found 1 SNP to be associated with the more loose definition of asthma remission, clinical remission. This SNP associated with POLI (Polymerase iota) expression in lung tissue. Human DNA polymerase iota (Polι) belongs to the Y family of specialized DNA polymerases and is one of the most error-prone enzymes involved in DNA synthesis. 35 The functions of Polι in human cells remain largely unknown, and it is not clear which might be the role of this gene in clinical asthma remission.
There are strengths and weaknesses to the current study. A strength of our approach is that both active asthma and asthma remission was defined using objective characteristics of the disease, that is bronchial hyperresponsivess, airway obstruction, in combination with the presence or absence of patient reported symptoms and medication use. Due to the use of different genotyping arrays,
we investigated "only" 156,954 SNPs that tagged 36%-60% of all SNPs in the genome. The term "genome-wide" is thus not really applicable to our study. Our study has a rich characterization of the asthmatics collected over a follow-up period of 3-47 years. Because of the detailed characterization, which included among others hyperresponsiveness both at baseline and follow-up visits, a strict asthma remission definition could be used. This reduced the number of asthmatics with complete remission to 55 in the identification cohort and 7 and 14 in the replication cohorts, EGEA and SALPALDIA,
respectively. This might theoretically lead to false-negative or spurious findings, but the fact that all 3 cohorts had the same direction and magnitude of effect of the identified SNPs in relation to complete asthma remission and that these genes had biologically plausible eQTLs may suggest that the study has identified promising new leads for further research on the mechanisms of asthma remission. Of interest, none of the replicated SNPs was an eQTL in epithelial cells, while these cells are thought to be fundamental to asthma development. 36 This suggests that either larger groups of patients should be studied to ensure that epithelial cells do not contribute to asthma remission, or that different inflammatory or resident cells in the lung may be important for asthma remission compared to those for asthma inception. The prevalence of asthma remission in the SAPALDIA study is higher than in the other 2 cohorts. This may be the result of the fact that the SAPALDIA study is a general population-based cohort while the other 2 cohorts are hospital-based studies that generally attract patients with more severe asthma.
In conclusion, we found suggestive evidence that a set of genes may contribute to asthma remission in a subset of asthmatics, using a strict definition of complete asthma remission. The study points to the value of deep phenotyping for the identification of novel drug targets through genetic epidemiology complemented with functional characterization of associated SNPs. We invite the scientific community to contribute to further characterization of asthmatics in a similar way to increase the numbers of asthmatics with complete remission to be studied with a genome-wide screen, thus allowing gene-gene interaction and epigenetic assessments as well, or even better to do so with whole genome sequencing as this may additionally elucidate rare variants and pinpoint genes that associate with such a rare, but extremely important phenotype of asthma: full remission!
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